[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"t2d\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:t2d":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100610584","potatoes-type-2-diabetes-and-cardiometabolic-health-100610584",false,"NCT07229482","Potatoes, Type 2 Diabetes, and Cardiometabolic Health","Cardiometabolic Effects of a Potato-rich Diet in Older Adults at Increased Risk of Developing Type 2 Diabetes: A Randomized Controlled Feeding Study","Inclusion Criteria:\n\n* Age 50-70 years\n* Weight stable for previous 3 months (±5% body weight)\n* Sedentary to recreationally active\n* ADA-Risk Screener questionnaire score of at least 5\n* No plans to gain or lose weight or change physical activity level\n* Willing to pick up food daily and consume foods provided for a 14-week period\n* Verbal and written informed consent\n* Estrogen or testosterone use, lipid-lowering or blood pressure medication and thyroid replacement medication is acceptable, if on stable dose for \\>6 months\n\nExclusion Criteria:\n\n* Body mass index \\>40 m2\u002Fkg\n* Diabetes or diabetes medication\n* Weight loss medication or medication influencing glucose metabolism\n* Antibiotic, prebiotic or probiotic use in prior 3 months\n* TCHOL \\>6.2 mmol\u002FL; TG \\>4.5 mmol\u002FL\n* Blood pressure (BP) \\> 159\u002F99 mmHg\n* Diagnosed inflammatory bowel disease\n* Past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease\n* Vegetarian or vegan\n* Pregnant or plans to become pregnant\n* Food allergies or aversions to diet foods provided\n* Estrogen or testosterone usage, lipid-lowering medication, blood pressure medication usage \\\u003C6 months",true,"ALL","50 Years","70 Years",{"count":21,"type":22},42,"ESTIMATED","INTERVENTIONAL",[25],"NA","Type 2 diabetes (T2D) is a major chronic health condition which increases risk of coronary artery disease, frailty, cognitive decline, and mortality. Additionally, hypertension is a major comorbidity for individuals with T2D, further increasing the risk of adverse cardiovascular outcomes. The prevalence of both conditions increases with advancing age. There is an urgent need to identify new approaches to prevent the development of T2D and improve cardiometabolic health in older adults 50-70 years of age.\n\nWhole white potatoes are an unprocessed food rich in essential nutrients often under-consumed by Americans, including potassium, fiber, magnesium, vitamins C and B6, and phytochemicals. Each of these nutrients individually are associated with cardiometabolic health benefits. Potatoes account for a significant amount of the intake of these nutrients in the US diet and are well-positioned to be a foundational element of a healthy dietary pattern. However, there are few interventional studies evaluating the effect of potatoes on cardiometabolic health, and the evidence from observational studies is mixed, leaving a significant gap in knowledge regarding the potential for potatoes to be included in healthy dietary patterns.\n\nThe results of our proposed study will provide foundational data that inform future dietary guidelines regarding the inclusion of white potatoes as part of a healthy US dietary pattern.",[28,29,30],"T2D","Blood Pressure","Cardiometabolic Health","RECRUITING","2026-07-31",{"date":34,"type":35},"2026-08-04","ACTUAL",{"date":37,"type":22},"2026-08",{"date":39,"type":22},"2029-03",{"name":41,"class":42},"Virginia Polytechnic Institute and State University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100644609","phase-1-bioequivalence-study-of-gzr4-injection-with-different-manufacturing-processes-in-healthy-adult-participants-100644609","NCT07670897","Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants","A Randomized, Open-label, Single-dose Study to Evaluate the Bioequivalence of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants","Inclusion Criteria:\n\n* 1\\. Voluntarily sign the Informed Consent Form (ICF), be willing to accept subcutaneous injection, fully understand the study content, procedures and potential adverse reactions, and be able to comply with the contraindications and restrictions specified in this protocol.\n\n  2\\. Male, aged 18 to 50 years (inclusive) at the time of ICF signing. 3. Body weight ≥ 50 kg and body mass index (BMI) within the range of 18.5 to 24.0 kg\u002Fm² (inclusive) at screening.\n\n  4\\. Male participants of childbearing potential have no plans for conception, voluntarily adopt effective contraceptive measures, and have no sperm donation plans from the date of ICF signing until 4 weeks after dosing.\n\nExclusion Criteria:\n\n* 1\\. Have an allergic constitution, or a history of allergic diseases such as bronchial asthma and eczema (except for mild seasonal allergy); or have a history of severe food allergy (e.g., laryngeal edema, shock); or known allergy, hypersensitivity or intolerance to the investigational medicinal product (IMP) or similar products or their excipients; or have a clinically significant history of drug allergy or atopic allergic diseases.\n\n  2\\. Findings from physical examination, vital signs, routine laboratory tests, 12-lead electrocardiogram (ECG), chest imaging and other assessments at screening are judged to be clinically significant by the investigator.\n\n  3\\. Have special dietary requirements and are unable to comply with the standardized diet.\n\n  4\\. Have a history of needle phobia or blood phobia, have difficulty in blood collection, or cannot tolerate venous puncture for blood sampling.\n\n  5\\. The participant is an employee of the investigator or the study center, or a family member of an employee or the investigator; or the participant has other factors that, in the investigator's opinion, make him\u002Fher unsuitable for participation in the study.","MALE","18 Years",{"count":54,"type":22},64,[56],"PHASE1","This study is a single-center, open-label, randomized, single-dose bioequivalence trial conducted in healthy adult participants.",[28],"NOT_YET_RECRUITING","2026-06-22",{"date":62,"type":35},"2026-06-26",{"date":64,"type":22},"2026-07-01",{"date":66,"type":22},"2026-07-29",{"name":68,"class":69},"Gan & Lee Pharmaceuticals.","INDUSTRY"]